Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.78 |
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444640 | 0.88 | MIF (1.00) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL6444643 | 0.88 | MIF (1.00) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL5373505 | 0.86 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL5373502 | 0.86 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL17290220 | 0.86 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL6443003 | 0.86 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL13903557 | 0.86 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL14902404 | 0.86 | RAB9A (1.00) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL6423387 | 0.86 | MAPT (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL12979794 | 0.86 | MAPT (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | MIF 894/4885RAB9A 3946/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.